A new online training programme, HPV VACs: Vaccinate Adolescents against HPV Cancers, has been launched by the International Pediatric Association (IPA) in collaboration with the American Cancer Society (ACS), marking International HPV Awareness Day.
This initiative aims to strengthen global efforts in HPV prevention by equipping healthcare professionals with practical knowledge and resources to support adolescent vaccination and reduce the burden of HPV-related cancers.
The course is available through the IPA Learning Management System and offers structured, accessible training for clinicians involved in child and adolescent health. Upon successful completion, participants will receive a certificate.
In addition to the course itself, a dedicated promotion toolkit has been developed to support wider dissemination, including ready-to-use materials for social media and professional networks. These resources are designed to help amplify awareness and encourage uptake among healthcare providers.
EAP encourages paediatricians and healthcare professionals across Europe to explore this initiative and consider enrolling in the training, as well as sharing it within their networks to support broader impact.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
